Simvastatin
- Generic Name
- Simvastatin
- Brand Names
- Cholib, FloLipid, Simcor, Vytorin, Zocor
- Drug Type
- Small Molecule
- Chemical Formula
- C25H38O5
- CAS Number
- 79902-63-9
- Unique Ingredient Identifier
- AGG2FN16EV
- Background
Simvastatin, also known as the brand name product Zocor, is a lipid-lowering drug derived synthetically from a fermentation product of Aspergillus terreus. It belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage abnormal lipid levels by inhibiting the endogenous production of cholesterol in the liv...
- Indication
Simvastatin is indicated for the treatment of hyperlipidemia to reduce elevated total cholesterol (total-C), low-density lipoprotein cholesterol (LDL‑C), apolipoprotein B (Apo B), and triglycerides (TG), and to increase high-density lipoprotein cholesterol (HDL-C).
...
- Associated Conditions
- Cardiovascular Events, Diabetes Mellitus, Heterozygous Familial Hypercholesterolemia (HeFH), High Cholesterol, Homozygous Familial Hypercholesterolaemia (HoFH), Mixed Hyperlipidemia, History of coronary heart disease cardiovascular event, History of stroke or other cerebrovascular disease cardiovascular event
- Associated Therapies
- -
7 Tesla MRI Study in Patients With Statin Related Muscle Complaints
- Conditions
- Interventions
- First Posted Date
- 2020-10-05
- Last Posted Date
- 2022-10-31
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Target Recruit Count
- 8
- Registration Number
- NCT04575090
- Locations
- 🇺🇸
UT Southwestern Medical Center, Dallas, Texas, United States
Neurotoxicity Prophylaxis With Intrathecal Dexamethasone and Simvastatin Post Axi-Cel
- Conditions
- Interventions
- First Posted Date
- 2020-08-14
- Last Posted Date
- 2024-02-26
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 37
- Registration Number
- NCT04514029
- Locations
- 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States
Coronavirus Response - Active Support for Hospitalised Covid-19 Patients
- First Posted Date
- 2020-04-13
- Last Posted Date
- 2020-11-19
- Lead Sponsor
- London School of Hygiene and Tropical Medicine
- Registration Number
- NCT04343001
- Locations
- 🇳🇬
University College Hospital, Ibadan, Oyo, Nigeria
🇵🇰Shifa Tameer-e-Millat University, Rawalpindi, Pakistan
A Study of LY3502970 in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2019-04-29
- Last Posted Date
- 2020-11-18
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 133
- Registration Number
- NCT03929744
- Locations
- 🇺🇸
Covance Dallas, Dallas, Texas, United States
Simvastatin in Secondary Progressive Multiple Sclerosis
- First Posted Date
- 2019-03-29
- Last Posted Date
- 2024-01-10
- Lead Sponsor
- University College, London
- Target Recruit Count
- 40
- Registration Number
- NCT03896217
- Locations
- 🇬🇧
Department of Neuroinflammation, UCL Institute of Neurology, London, United Kingdom
Phase IB Metformin, Digoxin, Simvastatin in Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2019-03-26
- Last Posted Date
- 2024-10-11
- Lead Sponsor
- Danae Hamouda, MD
- Target Recruit Count
- 15
- Registration Number
- NCT03889795
- Locations
- 🇺🇸
University of Toledo, Eleanor N. Dana Cancer Center, Toledo, Ohio, United States
Safety and Tolerability Study of Ezetimibe (SCH 058235/MK-0653) Plus Atorvastatin or Simvastatin in Homozygous Familial Hypercholesterolemia (P01417/MK-0653-019)
- Conditions
- Interventions
- First Posted Date
- 2019-03-22
- Last Posted Date
- 2022-02-17
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 44
- Registration Number
- NCT03885921
Ezetimibe (SCH 58235) Taken With Either Atorvastatin or Simvastatin in Participants With Familial Hypercholesterolemia (MK-0653-018)
- Conditions
- Interventions
- First Posted Date
- 2019-03-21
- Last Posted Date
- 2024-05-10
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 50
- Registration Number
- NCT03884452
Drug-Drug Interaction Study of Vadadustat With Rosuvastatin, Sulfasalazine, Pravastatin, Atorvastatin and Simvastatin
- Conditions
- Interventions
- First Posted Date
- 2019-01-11
- Last Posted Date
- 2019-03-22
- Lead Sponsor
- Akebia Therapeutics
- Target Recruit Count
- 134
- Registration Number
- NCT03801733
- Locations
- 🇨🇦
InVentiv Health Clinique Inc., Québec City, Quebec, Canada
Efficacy of the Combination of Simvastatin Plus Rifaximin in Patients With Decompensated Cirrhosis to Prevent ACLF Development
- Conditions
- Interventions
- First Posted Date
- 2018-12-19
- Last Posted Date
- 2023-05-24
- Lead Sponsor
- Judit Pich
- Target Recruit Count
- 254
- Registration Number
- NCT03780673
- Locations
- 🇫🇷
Beajuon Hospital, Clichy, Paris, France
🇳🇱Academic Medical Centre, Amsterdam, Netherlands
🇪🇸Hospital Universitari Vall d'Hebrón, Barcelona, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.